The FDA last week approved Pfizer’s Abrilada, the fifth biosimilar to AbbVie’s Humira set to hit the market when the company’s US patent expires in 2023. For the treatment of rheumatoid arthritis in the pharmacy benefit, Humira holds preferred formulary status for 8% of covered lives, growing to 61% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 11/21/19